Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer
Authors:
- 1 November 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (21) , 4394-4400
Abstract
Purpose: Tumor growth and metastasis is believed to depend on the tumor's ability to induce neovascularization. Recent studies have indicated that thalidomide inhibits angiogenesis. We performed a phase I and pharmacokinetic study of thalidomide with carboplatin in children with refractory solid tumors. Patients and Methods: Carboplatin was administered as a single intravenous dose once every 21 days at a target area under the concentration-time curve of 6 mg/mL·min. Thalidomide was administered daily by mouth. The initial dose level was 100 mg/m2/d with intrapatient dose escalation to a maximum dose of 300 mg/m2/d. The next cohort of patients started at a dose of 300 mg/m2/d, with intrapatient dose escalation to a maximum dose of 500 mg/m2/d. Standard response and adverse event criteria were used. Serial blood samples for thalidomide pharmacokinetics studies were obtained after the first dose. Results: Twenty-two patients received 56 cycles of therapy. The maximum tolerated thalidomide dose was 400 mg/m2/d. The dose-limiting toxicity was somnolence. There were no objective responses. Thalidomide's apparent clearance was 55 ± 16 mL/min/m2 and the terminal half-life was 5.9 ± 2.8 hours. There was no evidence of dose-dependent pharmacokinetics in the narrow range studied. Conclusion: Thalidomide at a dose of 400 mg/m2/d can be safely administered to children with solid tumors in combination with carboplatin. Somnolence is the major toxicity. In addition, we have characterized the pharmacokinetic behavior of thalidomide in children. This study can serve as the basis for future investigation of thalidomide as an anticancer agent in children.Keywords
This publication has 36 references indexed in Scilit:
- Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on SurvivalClinical Lymphoma, 2003
- Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatmentJournal of Thrombosis and Haemostasis, 2003
- Adverse Reactions to Thalidomide in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1997
- Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1997
- A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serumAnalytica Chimica Acta, 1997
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- Pharmacokinetics1982
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978